RESEARCH TRIANGLE PARK, N.C., June 25 /PRNewswire-FirstCall/ -- Ruedi Waeger, Ph.D., former president and CEO of Aventis Behring LLC and a member of the Talecris Board of Directors, was honored with the Robert W. Reilly Leadership award June 15 at the 2010 Plasma Protein Forum in Reston, VA.
The award is sponsored by the Plasma Protein Therapeutics Association (PPTA) and recognizes individuals who exemplify the leadership qualities of Robert Reilly, former leader of the PPTA. Reilly's efforts improved the quality of plasma products in the U.S. and enhanced the reputation of the plasma therapeutics industry worldwide.
Waeger was bestowed the award because of his significant contributions toward improving patient access to therapies, ensuring the highest quality and safety of plasma-derived products, and striving to achieve worldwide regulatory standardization of protein therapies.
"Ruedi's accomplishments throughout his 30-year career have contributed immensely to the field of protein therapeutics, and we are pleased that his accomplishments have been recognized by the industry," said Lawrence D. Stern, chairman and CEO of Talecris. "Ruedi's breadth of knowledge and experience continue to be tremendously valuable to Talecris, and we congratulate him on having received this honor from the PPTA."
Waeger has served on the Talecris Board since April 2005 and currently chairs the compliance committee. He also serves on the nominating and governance committees. Waeger has more than 30 years of experience in the global pharmaceutical and therapeutic protein industries. Prior to joining the Talecris board, Waeger served as President and CEO of the plasma therapeutics company Aventis Behering LLC. Prior to that, he served as President and CEO of ZLB Central Laboratories and the Blood Transfusion Service of the Swiss Red Cross. Waeger earned a Ph.D. in biochemistry from the Swiss Federal Institute of Technology.
About the Robert W. Reilly Leadership Award
Robert Reilly was a leader in the plasma therapeutics industry association from 1992 to 1998. He created the first educational programs and industry symposia to confront the challenges facing the plasma industry worldwide. He also contributed significantly to the development of voluntary industry standards for quality plasma programs throughout the U.S., and his work helped open communications and build relationships with regulatory authorities and consumer groups.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com
SOURCE Talecris Biotherapeutics, Inc.